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Purpose: To evaluate the pharmacokinetics of nifedipine in healthy adult Pakistani subjects.  
Methods: Each of six fasting volunteers received 20 mg nifedipine (2 x Adalat
®
 10 mg capsules) orally 
once and then another one week later. Their blood samples were obtained at regular time intervals and 
analysed by HPLC. Using the non-compartmental approach, plasma levels of nifedipine were employed 
to compute their individual disposition kinetics, including Cmax (maximum plasma concentration), Tmax 
(time to reach maximum plasma concentration), MRT (mean residence time), AUC0-∞ (area under 
curve), AUMC0-∞ (area under first moment curve) and Ka (absorption rate constant). 
Results: The suggested therapeutic level of nifedipine for the treatment of hypertension (15-35 ng.mL
-1
) 
was achieved in all six volunteers within 0.25 h after dose administration, and maintained for more than 
6 h. Tmax was 1.58 h and Cmax varied from 140 – 300 ng.mL
-1
. Mean absorption rate constant was 2.22 
h
-1 
while mean absorption half-life was 0.43 h. The mean elimination rate constant was 0.16 h
-1
 while 5.7 







 and 4.2 h, respectively.  
Conclusion: This study confirms the rapid absorption of nifedipine in humans. AUC was similar to that 
previously reported for Nigerians but slightly lower than that stated in the literature for other south Asian 
races. Further studies on large segments of the local population using the non-compartmental model for 
kinetic analysis is recommended. 
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INTRODUCTION 
 
Nifedipine is a dihydropyridine calcium-
channel blocker. It is used for the treatment 
of hypertension and angina pectoris. 
Pharmacokinetics of nifedipine differs in 
different populations. [1] There are numerous 
publications on the bioavailability and 
pharmacokinetics of nifedipine [1-3] but no 
work on the pharmacokinetics of nifedipine in 
the Pakistani population has been reported 
previously, to the best of our knowledge. 
Such a study would be important since it 
should provide useful information on drug 
blood levels and metabolic status [4-7] which 
could influence the use of this drug among 
Pakistanis. Furthermore, some dosage 
adjustments may be needed, based on 
pharmacokinetic data, for patients in this 
region of the world [8-10].  
 
Therefore, the present work was undertaken 
to evaluate the pharmacokinetic parameters 
of nifedipine in the Pakistani population 
following a single oral dose administration, 
compare the data obtained with those 
reported for a couple of other populations, 
and  suggest a more rational dosage 




Subjects, formulation and study design 
 
This study involved six healthy, adult, non-
smoking male Pakistani volunteers with no 
revealed medical abnormality. Informed 
written consent was obtained from the 
volunteers. The experimental protocol was 
approved by the Board of Advance Studies 
and Research (Institutional Ethical 
Committee), the University of Bahawalpur, 
Pakistan and was conducted according to the 
Helsinki Declaration. Informed consent was 




 capsules, 10 mg, Bayer 
Pharmaceuticals, Karachi, Pakistan) was the 
drug used. The study was conducted in the 
same subjects in two phases separated by a 
washout period of one week. Twelve data 
sets were obtained. 
 
Drug administration and blood sampling 
 
A blank blood sample (at 0 h) was drawn 
from each volunteer before the ingestion of 
20 mg nifedipine (2 x 10 mg tablets) with 250 
mL of water. Blood samples (5 - 7 mL) were 
collected using heparinzed disposable 
syringes and plain glass tubes at the 
following intervals: 0.25, 0.50, 0.75, 1.0, 1.5, 
2, 3 and 6 h after drug administration. The 
samples were centrifuged at 3,000 rpm for 15 





Sample treatment and data analysis 
 
To a 3 mL stoppered vial, 1 mL plasma was 
taken and extracted first with 2 mL ethyl 
acetate and then with 1mL ethyl acetate. Two 
millitres of the ethyl acetate layer was placed 
in a 5 mL glass tube and dried under vacuum 
at 45 °C [11]. 
 
Equal volumes of acetonitrile and phosphate 
buffer (pH 6.8) were mixed gently to 
constitute the mobile phase. The dried ethyl 
acetate extract was reconstituted in 0.5 mL of 
mobile phase. A 20 µl sample was injected 
into the HPLC system (Shimadzu, Japan) 
operated with a spectrophotometeric variable 
detector using a reverse phase C-18 HPLC 
column (Waters, USA). Flow rate was 1.3 
mL/minute at ambient temperature. 
Quantitation was achieved by comparing the 
peak height of nifedipine in plasma to those 
of plasma samples spiked with various 
concentrations of nifedipine. 
 
Using the non-compartmental approach, 
plasma levels of nifedipine were employed to 
compute their individual disposition kinetics, 
viz, Cmax (maximum plasma concentration), 
Tmax (time to reach maximum plasma 
concentration), MRT (mean residence time), 
AUC0-∞ (area under curve) AUMC0-∞ (area 
under first moment curve) and Ka (absorption 
rate constant). 
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RESULTS  
 
The plasma levels of nifedipine (mean ± 
SEM, n = 12) are given in Fig 1(a). Tmax was 
achieved 1.58 h after drug administration 
while Cmax was 210.33 ng.mL
-1
. The 
suggested nifedipine therapeutic range for 
hypertension (15-35 ng/mL) was achieved in 
all the volunteers within 0.25 h after dose 
administration and maintained for more than 
6 h. Mean Ka was 2.22 h
-1
 with a mean 
absorption half-life (k1/2α) of 0.43 min. Cmax 
was followed by a concentration decay that 
could be fitted to a straight line on semi-
logarithmic scale, indicating first order mode 
of elimination.  
 
Fig 1 (b) and (c) show the pharmacokinetic 
analysis of mean plasma levels by one-
compartmental model and of three data sets 
by two-compartmental model, respectively, 
while pharmacokinetic parameters obtained 
by fitting the data to one- or two-compartment 
model are given in Table 1. The data largely 
indicate single compartmental behavior and 
only three data sets revealed two-
compartmental behavior. Terminal half-lives 
observed in single and two compartments 
were very different. The half-life of two 
compartmental profiles was comparatively 
high compared to that of one-compartmental 
model. Mean elimination rate constant was 
0.16 h
-1 
and terminal half-life 5.7 h. AUC0-t 
and AUC0-∞ were 942 and 1879 ng.h.mL
-1
, 













Ethnic differences and bioavailability of 
nifedipine 
 
Nifedipine bioavailability after oral 
administration in healthy human volunteers of 
different populations reported in previous 
studies differed from ours. Table 2 shows 
bioavailability data from the present work 
alongside those reported for some parts of 
the world. It should be noted that oral 
nifedipine bioavailability, estimated as AUC, 
was significantly greater in Japanese, 
Nigerian and South Asian subjects than in the 
Caucasian and German. The Dutch authors 
did not provide AUC values in their report. 
The results observed with 10 mg nifedipine 
administration showed that AUC in Mexicans 
was significantly (p < 0.05) higher than in 
German, Taiwani, American and English 
subjects. According to literature, mean AUC 
values were twice those observed for white 
individuals [12]. 
 
Since it has been demonstrated that the 
pharmacokinetics of oral nifedipine at these 





Fig 1: (a) Mean ± SEM plasma concentration 
profile (b) Pharmacokinetic analysis of mean 
plasma profile, and (c) plasma level profile of 3-set 
data, obtained after oral administration of 2 × 10 
mg nifedipine in capsule form. 
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Table 1: Pharmacokinetic parameters for nifedipine following a 20mg single oral dose administration 
to Pakistani subjects  
 































































































































A 261 2.00 4.90 4.45 1245.00 1.289 0.000 0.141 0.54 0.00 4.90 
B 277 0.50 3.14 4.30 957.12 0.982 0.000 0.221 0.71 0.00 3.14 
C 176 0.75 7.45 5.27 921.75 6.713 0.903 0.093 0.10 0.77 7.45 
D 250 0.75 4.81 2.45 1004.00 1.085 0.000 0.144 0.64 0.00 4.81 
E 154 1.50 4.25 4.41 1381.88 1.594 0.000 0.163 0.43 0.00 4.25 
F 207 2.00 4.62 3.86 1224.75 1.906 0.000 0.150 0.36 0.00 4.62 
G 151 1.50 3.87 4.01 729.38 0.986 0.000 0.179 0.70 0.00 3.87 
H 194 1.00 3.89 4.50 661.12 1.082 0.000 0.178 0.64 0.00 3.89 
I 208 2.00 6.13 4.48 933.75 2.822 0.000 0.113 0.25 0.00 6.13 
J 269 1.50 17.3 4.30 829.88 2.410 0.751 0.040 0.29 0.92 17.33 
K 140 2.00 6.36 4.19 662.88 2.119 0.790 0.109 0.33 0.88 6.36 
L 300 1.50 1.70 4.20 753.25 3.684 0.00 0.407 0.19 0.00 1.70 
Mean 210 1.58 5.70 4.2 942.06 2.22 0.20 0.16 0.43 0.21 5.70 
 
Table 2: Absorption parameters (mean ± SEM) of nifedipine following oral administration of a single 
dose to healthy volunteers in various populations of the world 
 




















German 38 ± 33 19.35 6 
Japanese 598 ± 10 29.9 6 
Nigerian 808 ± 250 40.4 11 
Caucasian 323 ± 116 16.15 27 
South Asian 802 ± 243 40.1 30 
Bengali 989 ± 166 49.45 6 
Pakistan 942 ± 72 47.10 12 
10-mg capsule/tablet dose 
English 148 ± 23 14.8 6 
English 154 ± 8 15.4 59 
USA 125 ± 5 12.5 12 
USA 145 ±12 14.5 15 
German 161 ± 24 16.1 8 
Mexican 384 ± 41 38.4 12 
Mexican 267 ± 22 26.7 6 
Taiwanese 294 ± 116 29.4 198 
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Table 3: Various pharmacokinetic parameters of nifedipine following oral administration of 20 mg dose to 
healthy volunteers in various populations of the world 
 
Area under the curve (AUC) for 
different populations corrected 






















Dutch 1.7 - - 6 116 1.4 
Mexican 2.1 - - - - - 
English 2.2 - - 12 - - 
Japanese 2.5 598 239 6 236 1.0 
USA 3.4  0 12 - - 
German 3.9 387 99 6 147 0.7 
Mexican 5.1 - 0 12 - - 
Nigerian 5 808 162 11 205 0.75 
Caucasian 2.7 323 120 27 172 0.5 
South Asian 6.5 802 123 30 241 0.5 
Bengali 8.3 989 119 6 250 0.8 
Pakistani 5.7 942 165 12 210.33 1.58 
Taiwanese - - - 198 143.12 3.08 
 
and slow release tablet (SRT) formulations 
are bio-equivalent (based on AUC), it is 
possible to compare overall absorption in 
healthy individuals from different populations 
independent of the dose and formulation 
used. This can be achieved if the 
bioavailability is expressed as AUC corrected 





These corrected values are listed in Table 2. 
Peak plasma levels and times reported in 
previous studies and in the present study are 
shown in Table 3. Cmax values are similar for 
the Dutch and German studies, but higher for 
the Japanese and much higher for the Bengali 
and south Asian populations. A similar result 
to that of the Nigerian population was obtained 
in the present study. Tmax ranged between 0.5 
and 2 h, indicating that nifedipine was rapidly 
absorbed in all the populations. In this respect, 
Germans, Japanese, Caucasians, and South 
Asians showed tmax of up to l h, while it was 
1.58 h for Pakistanis which is similar to that for 
the Dutch study, indicating identical rate of 
drug absorption in these populations. 
 
Ethnic differences and other nifedipine 
pharmacokinetics 
 
Some previous investigators postulated that 
populations may be characterised as either 
fast or slow absorbers of nifedipine [4,6]. 
Similarly, while some showed high 
bioavailability and there were others who 
showed low availability [10]. However, in our 
opinion, these differences could be related to 
the biological half-life of the drug. The 
apparently higher AUCs in some populations 
do not necessarily mean higher bioavailability 
but rather longer stay in the body due to slow 
elimination. In this context, the 
pharmacokinetic picture changes completely. 
Table 3 lists AUC/t1/2 values derived from the 
present and some other studies. For 
example, south Asian, Bengali and Pakistani 
populations who showed apparently high 
bioavailability now manifested average 
bioavailability with AUC/t1/2 ratio of between 
120 and 165, while the ratio for the Japanese 
rises to 239 and that for the Germans is 
lowest at 99. In our opinion, the bioavailability 
of the nifedipine is not erratic or different 
across populations, but rather, genetic and 
biochemical factors in different populations 
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probably produce differences in the 
elimination and distribution kinetics of the 
drug.  
 
Absorption kinetics in Asians, compared to 
white volunteers, is high. Previous studies 
also reported a very marked scatter in 
individual plasma levels during the absorption 
phase, but did not provide any ka data [5,14]. 
The authors of the latter study attributed this 
variability to differences in gastrointestinal 
absorption and/or hepatic first pass extraction 
and metabolism. They proposed two distinct 
groups of fast and slow absorbers with Tmax 
of less than 2 and more than 2 h, 
respectively. According to this criterion, all 
the subjects in our study were fast absorbers 
(tmax = 0.5-2 h). 
 
We observed that the distribution phase can 
only be clearly seen in very few data sets. In 
three subjects C, J & K plasma 
concentration-time curves were 
distinguishable and data could be acceptably 
fitted to a two-compartment model. In the 
other 9 subjects, the distribution phase was 
evidently rapid and one-compartment model 
could only fit to the data. The one- and two-
compartmental analyses have been 
graphically illustrated in Fig 1 (b) and (c). 
 
It is known that the presence of a clearly 
differentiated distribution phase in plasma 
concentration-time curves fitted by a two-
compartment model depends on the 
relationship between the absorption and 
distribution rate constants, ka and kα. It was 
observed that within the range of distribution 
values obtained, subjects with a ka/kα ratio > 
1.5 presented plasma concentration-time 
curves with a sharp peak and a clearly 
evident distribution phase. In those subjects 
where the ka/kα ratio was lower than 1.5, the 
curves were flattened and distribution phase 
was not apparent. These findings were 
confirmed by constructing sets of plasma 
concentration-time curves by computer 
simulation, varying the ka and kα value. For 
data sets C, J and K, the values of ka were 
found to be 6.713, 2.410 and 2.119, 
respectively h
-1
 while kα for these subjects 
were 0.903, 0.751 and 0.790 h
-1
, respectively. 
The ratio ka/kα for these subjects was of the 
order 7.43, 3.21 and 2.68, respectively. That 
is why the data sets of these subjects are 
best fitted by the two-compartmental model 
while others could be explained by one-
compartment model.  
 
The mean elimination half-life (t1/2β) obtained 
in this study was higher than the values 
reported by other authors for European and 
North American populations. It is worth 
mentioning that a marked inter-individual 
variability was observed in this parameter, 
the range being 1.6 to 9.1 h. Mean elimination 
half-life in this study was 5.09 h. The values 
show that there is a clear difference between 
the data from sub-continental studies and 
those from other studies. There is some 
controversy concerning the actual terminal t1/2 
of nifedipine. Table 3 shows t1/2 values that 
have been reported for healthy subjects from 
different populations after capsule 
administration (10 or 20 mg). Unlike AUC and 
Cmax, there was no clear distinction between 
populations of different ethnic origins. To 
overcome the inter-subject variability in tl/2β in 
many of the previously reported studies and 
the present work, we computed the mean 
residence time (MRT) by non compartmental 
model. It can be seen very clearly that the 
coefficient of variance (CV) of MRT is very 
low in comparison to the CV of tl/2β (Table 1). 
The low CV of MRT proves the suitability of 




We can conclude that for the study of 
nifedipine pharmacokinetics, the non-
compartment model appears to be more 
useful. Unfortunately, none of the previous 
researchers reported MRT data to enable 
comparison with the MRT obtained in the 
present work. It would also be necessary to 
carry out a more extensive study on larger 
segments of the Pakistani population for 
more definitive conclusions and comparisons 
to be made with other regional populations. 
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